Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Inclusion Criteria: * Fully understand and voluntary sign the informed consent form,and be able to complete the study according to the protocol; * 18 years ≤ age ≤65 years; * Physical examination, vital signs, clinical laboratory examination and various examinations are normal or abnormal without clinical significance; * Agree to take effective contraceptive measures throughout the study period (including not limited to: physical contraception, hormonal drugs of pregnancy, surgery, abstinence, etc.,) until at least 10 months after the last study is administered; * Body weight ≥50 kg, 19kg/m2≤BMI≤26kg/m2; * Serum calcium level between 2.15\~2.55mmol/L（including the boundary value）; * Normal or clinically acceptable electrocardiogram (12-lead ECG), QTcB\<450msec. Exclusion Criteria: * Drink 14 units of alcohol per week within 3 months prior to administration, or take any alcohol substance within 48 hours before subcutaneous injection; * Substance abuse within 5 years before subcutaneous injection; * Smoke more than 5 cigarettes per day or the same amount of tobacco within 3 months before subcutaneous injection; * Allergic constitution; * Drink excessive amounts of tea, coffee or caffeinated beverages within 30 days before subcutaneous injection; * Use any prescription, over-the-counter, vitamin or herbal medicine within 30 days before subcutaneous injection; * Bone surgery was performed within 30 days before administration; * History of osteomyelitis or osteonecrosis of the jaw; * Inflammation or abnormalities in or around the site of administration; * Needle or blood sickness; * Dental disease or jaw disease requiring oral surgery, dental surgery; or plan to have dental surgery during the study; * Received the study drug(including Xgeva and Prolia), or participated in a clinical trial within 3 months prior to administration； * Received living viraL vaccine within 3 months prior to administration; * Blood donation or blood loss \>400ml within 3 months prior to administration; * Hepatitis B surface antigen was positive, and/or hepatitis C antibody was positive; * The HIV antibody test was not negative; * Syphilitic test was positive; * Drug was detected in the urine; * Hyperparathyroidism, hypothyroidism, rheumatoid arthritis, Ankylosing Spondylitis, osteomalacia, Paget's disease, or fracture within 6 months; * History of severe lumbar disc herniation; * Insanity or legal problem are exist; * Plan to engage in strenuous physical labor or exercise during the study; * Other conditions that made it difficult to participate the study.